Introduction: Patients with COVID-19 are characterised by abnormal levels of inflammatory biomarkers. Elevated D-dimer in COVID-19 patients is associated with increased mortality. This study aimed to find out the prevalence of raised D-dimer among COVID-19 patients in a tertiary care centre. Methods: This descriptive cross-sectional study was conducted in COVID-19 unit of a tertiary care centre from 23 January 2021 to 19 June 2021. The ethical approval was taken from the Institutional Review Committee (Reference number: 077/078/159). D-dimer values and demographic data of the hospital-admitted COVID-19 patients were recorded. Convenience sampling technique was used. Point estimate and 95% Confidence Interval were calculated. Results: Out of 180 patients with COVID-19 admitted in the hospital, the D-dimer levels were raised in 85 (47.22%) (39.93-54.51, 95% Confidence Interval) patients. Conclusions: The prevalence of raised D-dimer among admitted COVID-19 patients was found to be lower when compared to other studies conducted in similar settings.

Background: Although many studies have reported the association of different factors with the severity of coronavirus disease (COVID) patients, no concrete scientific conclusions have been reported till date. Aim and Objective: This study aimed to conduct a prospective analysis on different factors associated with the severity and outcome of the COVID-19 patients. Materials and Methods: The study was conducted in a 100-bedded hospital of West Nepal for 3 months, with the total number of hospitalized patients 78. Demographic data, pre-existing comorbidities, ABO blood group, high-resolution computed tomography (CT) severity score, and outcomes of the respondents were recorded and analyzed statistically using Chi-square, binomial regression test, and significance level was considered P<0.05 at 95% confidence intervals. Results: Although the improvement rate was higher among males (84.0%) than females (75.0%), no significant association was observed between sex of the patient and treatment outcomes. Similarly, no significant association was observed in between age and ABO blood grouping of patients and treatment outcome. Furthermore, the chance of improvement is about 6 times higher (OR-6.214, 95% CI: 1.452–26.599; P=0.014) among patients with single comorbidity compared with patients with two or more comorbidities. Moreover, the chance of improvement is 8 times higher (OR-8, 95% CI: 2.034–31.461; P=0.001) in patients with CT severity score 1–15 compared with patients with CT severity score 16–25. Conclusion: CT severity score and pre-existing comorbid conditions play an important role among the different associated factors with the severity and treatment outcomes of COVID-19 patients.